ESR1 and breast carcinoma: Other studies have attempted to use alpelisib for neoadjuvant treatment of breast cancer, but the results of the NEO-ORB phase II study showed that alpelisib combined with letrozole for ER+/HER2− and early-stage breast cancer had no additional clinical benefit [84].